275 related articles for article (PubMed ID: 37393728)
1. Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation.
Selvaraj V; Khan MS; Mufarrih SH; Kazimuddin M; Waheed MA; Tripathi A; Bavishi C; Hyder ON; Aronow HD; Saad M; Abbott JD
Am J Cardiol; 2023 Aug; 201():260-267. PubMed ID: 37393728
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants or vitamin K antagonists after TAVR: A systematic review and meta-analysis.
Oliveri F; Montalto C; Tua L; Lanzillo G; Compagnoni S; Fasolino A; Gentile FR; Ferlini M; Pepe A; Oltrona Visconti L; Bongiorno A; Leonardi S
Int J Cardiol; 2022 Oct; 365():123-130. PubMed ID: 35901908
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists After Transcatheter Aortic Valve Implantation.
Ueyama H; Kuno T; Ando T; Briasoulis A; Fox J; Hayashida K; Takagi H
Am J Cardiol; 2020 Apr; 125(7):1102-1107. PubMed ID: 31964500
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K oral anticoagulants versus vitamin K antagonists in post transcatheter aortic valve replacement patients with clinical indication for oral anticoagulation: A meta-analysis.
Chen YF; Liu F; Li XW; Zhang HJ; Liu YG; Lin L
Clin Cardiol; 2022 Apr; 45(4):401-406. PubMed ID: 35191074
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.
Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
[TBL] [Abstract][Full Text] [Related]
6. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
[TBL] [Abstract][Full Text] [Related]
7. Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry.
Tanawuttiwat T; Stebbins A; Marquis-Gravel G; Vemulapalli S; Kosinski AS; Cheng A
J Am Heart Assoc; 2022 Jan; 11(1):e023561. PubMed ID: 34970918
[TBL] [Abstract][Full Text] [Related]
8. Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis.
Lee WC; Shih JY; Fang HY; Wu PJ; Fang CY; Chen HC; Fang YN; Chang WT; Chen MC
Clin Appl Thromb Hemost; 2023; 29():10760296231158585. PubMed ID: 36815218
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.
Yan J; Liu M; Zhang Y; Yang D; An F
Clin Cardiol; 2022 Oct; 45(10):1002-1010. PubMed ID: 36030549
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis.
Ge J; Han W; Ma C; Maduray K; Chen T; Zhong J
Clin Appl Thromb Hemost; 2022; 28():10760296221145168. PubMed ID: 36524251
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation.
Ooi AJQ; Wong C; Tan TWE; Ng TP; Teo YN; Teo YH; Syn NL; Djohan AH; Lim Y; Yeo LLL; Tan BYQ; Chan MY; Poh KK; Kong WKF; Chai P; Yeo TC; Yip JW; Kuntjoro I; Sia CH
Eur J Clin Pharmacol; 2022 Oct; 78(10):1589-1600. PubMed ID: 35941300
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
[TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.
Memon MM; Siddiqui AA; Amin E; Shaikh FN; Khan MS; Doukky R; Krasuski RA
Catheter Cardiovasc Interv; 2022 Jun; 99(7):2101-2110. PubMed ID: 35476221
[TBL] [Abstract][Full Text] [Related]
15. DOAC versus VKA in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis.
Guardia Martínez P; Avilés Toscano AL; Martínez Mayoral MA; Moltó Miralles J
Rev Esp Cardiol (Engl Ed); 2023 Sep; 76(9):690-699. PubMed ID: 36804556
[TBL] [Abstract][Full Text] [Related]
16. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
[TBL] [Abstract][Full Text] [Related]
17. Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
Hengstenberg C; Van Mieghem NM; Wang R; Ye X; Shi L; Guo S; Chen C; Jin J; Ye X; Dangas G; Unverdorben M
Am J Cardiol; 2023 Dec; 209():212-219. PubMed ID: 37848174
[TBL] [Abstract][Full Text] [Related]
18. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation.
Butt JH; De Backer O; Olesen JB; Gerds TA; Havers-Borgersen E; Gislason GH; Torp-Pedersen C; Søndergaard L; Køber L; Fosbøl EL
Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):11-19. PubMed ID: 31665260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
